Literature DB >> 16373429

Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum.

Santiago Ramón-García1, Carlos Martín, José A Aínsa, Edda De Rossi.   

Abstract

OBJECTIVES: The aim of this study was to characterize the efflux pump Tap from Mycobacterium fortuitum, to test its sensitivity to well known efflux inhibitors, to study the interaction between tetracycline and these compounds and to test the ability of these compounds to overcome efflux pump-mediated tetracycline resistance. For all these studies, we produced Tap protein in Mycobacterium smegmatis.
METHODS: Antibiotic susceptibility tests, tetracycline uptake/efflux experiments and checkerboard synergy tests.
RESULTS: Tetracycline uptake/efflux experiments showed that Tap protein from M. fortuitum uses the electrochemical gradient across the cytoplasmic membrane to extrude tetracycline from the cell. This efflux activity is inhibited by carbonyl cyanide m-chlorophenylhydrazone (CCCP) and reserpine, consistent with the decrease in MIC observed in antibiotic susceptibility testing in the presence of these inhibitors. Accumulation was not inhibited in experiments in which o-vanadate and chlorpromazine (CPZ) were tested. Inhibitor-treated cells used glycerol as a carbon source to re-establish the electrochemical gradient across the membrane and to restore efflux activity. CCCP, reserpine and CPZ reduced the MIC of tetracycline in the M. smegmatis strain expressing the Tap protein, whereas o-vanadate increased the MIC. We also observed synergy between tetracycline and CPZ or reserpine, and antagonism with o-vanadate.
CONCLUSIONS: The Tapfor efflux pump uses the electrochemical gradient to extrude tetracycline from the cell. This efflux activity can be inhibited by several compounds. This suggests that similar compounds could be used to overcome antibiotic resistance mediated by efflux pumps.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373429     DOI: 10.1093/jac/dki436

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery.

Authors:  Meenakshi Balganesh; Sanjana Kuruppath; Nimi Marcel; Sreevalli Sharma; Anju Nair; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.

Authors:  Meenakshi Balganesh; Neela Dinesh; Sreevalli Sharma; Sanjana Kuruppath; Anju V Nair; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator.

Authors:  Marco Bellinzoni; Silvia Buroni; Francis Schaeffer; Giovanna Riccardi; Edda De Rossi; Pedro M Alzari
Journal:  J Bacteriol       Date:  2009-10-09       Impact factor: 3.490

5.  Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.

Authors:  Santiago Ramón-García; Carlos Martín; Charles J Thompson; José A Aínsa
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

6.  WhiB7, an Fe-S-dependent transcription factor that activates species-specific repertoires of drug resistance determinants in actinobacteria.

Authors:  Santiago Ramón-García; Carol Ng; Pernille R Jensen; Manisha Dosanjh; Jan Burian; Rowan P Morris; Marc Folcher; Lindsay D Eltis; Stephan Grzesiek; Liem Nguyen; Charles J Thompson
Journal:  J Biol Chem       Date:  2013-10-14       Impact factor: 5.157

7.  Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Authors:  Santiago Ramón-García; Carol Ng; Hilary Anderson; Joseph D Chao; Xingji Zheng; Tom Pfeifer; Yossef Av-Gay; Michel Roberge; Charles J Thompson
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

8.  Transcriptional Profiling of Mycobacterium tuberculosis Exposed to In Vitro Lysosomal Stress.

Authors:  Wenwei Lin; Paola Florez de Sessions; Garrett Hor Keong Teoh; Ahmad Naim Nazri Mohamed; Yuan O Zhu; Vanessa Hui Qi Koh; Michelle Lay Teng Ang; Peter C Dedon; Martin Lloyd Hibberd; Sylvie Alonso
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

9.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

10.  Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.

Authors:  Tianyu Zhang; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.